摘要
目的:探讨阿立哌唑与奥氮平治疗老年精神分裂症患者的疗效和安全性。方法:对71例老年精神分裂症患者分别给予阿立哌唑与奥氮平治疗,其中阿立哌唑组36例,剂量为每日(12.18±2.56)mg,奥氮平组35例,剂量为每日(13.07±3.71)mg;疗程共8周。采用阳性和阴性症状量表(PANSS)和不良反应量表(TESS),在治疗前及治疗后第1、2、4、8周末分别评定疗效和不良反应。结果:(1)阿立哌唑和奥氮平的有效率分别为86.1%和91.4%,疗效的差异无显著性(P>0.05)。(2)两组治疗后第1周末至第8周末与治疗前的PANSS评分比较,差异有非常显著性(P<0.01)。(3)两组间从治疗第1周末起,各时点PANSS减分率差异无显著性(P>0.05)。(4)TESS评定显示,两组药物不良反应不同,总的不良反应发生率阿立哌唑组低于奥氮平组,但差异无显著性(x2=0.063,P>0.05)。结论:阿立哌唑与奥氮平对老年精神分裂症的疗效相当,均安全有效,但二者的不良反应不同,在治疗过程中应依个体化原则进行选择。
Objective：To study the efficacy and safe of aripiprazole and olanzapine in the treatment of the elderly patients with schizophrenia. Methods：Seventy- one elderly patients with schizophrenia were recruited in the present study, with 36 treated with Aripiprazole （ 12.18 ± 2.56） mg per day and 35 with Olanzapine （ 13.07 ± 3.71 ）mg per day ; And the therapy persisted 8 weeks. The Positive and Negative symptom scale（PANSS） and Emergent symptoms scale（TESS） were used to measure therapeutic efficacy and side effects before and at the end of 1. 2. 4. 8 weeks of treatment respectively. Results： （ 1 ） The rate of improvement was similar between Aripiprazole group and Olanzapine group （86.1% VS 91.4%, P 〉 0.05 ）. （2） The PANSS scores in two groups were significantly decreased from the first weekend to the eighth weekend after treatment and before treatment（ P 〈 0.01 ）. （ 3 ） The decrease radio of PANSS score between two groups had no significant difference at any time point from the first weekend after treatment（P 〉 0.05 ）. （4）TESS showed that the adverse drug reaction in two groups were different, the overall incidence of adverse reactions State Aripiprazole group had be lower than the Olanzapine group, but no significant difference （x2 = 0. 063, P 〉 0.05 ）. Conclusions ： State of Olanzapine and Aripiprazole on curative effect of senile schizophrenia are safe and effective, but a combination of adverse reactions to different, we should be carried out according to the principle of individual choice in the course of treatment.
出处
《中国民康医学》
2011年第23期2896-2897,2899,共3页
Medical Journal of Chinese People’s Health
